1 2 aim

Sarepta receives negative CHMP re-examination opinion for eteplirsen

This morning, Sarepta announced that following its request for re-examination, the Committee for Human Medicinal Products (CHMP) in Europe issued a negative opinion for eteplirsen. Relying upon Scientific Advisory Group input, Sarepta will seek further scientific advice from European Medicines Agency on a possible path to bring eteplirsen to patients in Europe.

Read here the official press release by Sarepta.

The EMA states on his meeting highlights from the CHMP 17-29 September 2018 that “The applicant for Exondys (eteplirsen) requested a re-examination of the Committee’s negative opinion for this medicine adopted at the May 2018 meeting. After considering the grounds for this request, the CHMP re-examined the initial opinion and confirmed its previous recommendation to refuse the granting of a marketing authorisation for this medicine.”

World Duchenne
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.